Edgewise Therapeutics, Inc. (EWTX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $1.10B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-500.00K; Retained Earnings (Accumulated Deficit)USD $-652.71M.
- 2026-03-31: Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $1.09B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-252.00K; Retained Earnings (Accumulated Deficit)USD $-595.38M.
- 2025-12-31: Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $1.07B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $677.00K; Retained Earnings (Accumulated Deficit)USD $-546.37M.
- 2025-09-30: Common Stock, Value, IssuedUSD $10.00K; Additional Paid in CapitalUSD $1.05B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $701.00K; Retained Earnings (Accumulated Deficit)USD $-496.15M.
Edgewise Therapeutics, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10.00K | $1.10B | $-500.00K | $-652.71M | $448.08M | 3 month · $9.36M |
| 2026-03-31 | $10.00K | $1.09B | $-252.00K | $-595.38M | $493.20M | 3 month · $8.71M |
| 2025-12-31 | $10.00K | $1.07B | $677.00K | $-546.37M | $522.26M | 12 month · $34.75M |
| 2025-09-30 | $10.00K | $1.05B | $701.00K | $-496.15M | $558.65M | 3 month · $8.09M |
| 2025-06-30 | $10.00K | $1.04B | $204.00K | $-455.49M | $589.07M | 3 month · $7.73M |
| 2025-03-31 | $9.00K | $848.68M | $401.00K | $-419.37M | $429.72M | 3 month · $9.06M |
| 2024-12-31 | $9.00K | $837.36M | $420.00K | $-378.58M | $459.22M | 12 month · $24.71M |
| 2024-09-30 | $9.00K | $826.73M | $1.05M | $-338.91M | $488.88M | 3 month · $6.88M |
| 2024-06-30 | $9.00K | $816.30M | $-1.05M | $-304.79M | $510.47M | 3 month · $5.22M |
| 2024-03-31 | $9.00K | $809.08M | $-861.00K | $-273.29M | $534.94M | 3 month · $4.87M |
| 2023-12-31 | $7.00K | $563.49M | $99.00K | $-244.76M | $318.83M | 12 month · $17.56M |
| 2023-09-30 | $6.00K | $505.46M | $-424.00K | $-214.62M | $290.43M | 3 month · $4.56M |
| 2023-06-30 | $6.00K | $500.90M | $-547.00K | $-188.91M | $311.45M | 3 month · $4.01M |
| 2023-03-31 | $6.00K | $496.52M | $-251.00K | $-167.44M | $328.84M | 3 month · $3.84M |
| 2022-12-31 | $6.00K | $492.67M | $-1.35M | $-144.60M | $346.72M | 12 month · $10.92M |
| 2022-09-30 | $6.00K | $488.76M | $-2.18M | $-125.19M | $361.40M | 3 month · $3.17M |
| 2022-06-30 | $5.00K | $356.37M | $-2.34M | $-107.69M | $246.35M | 3 month · $2.04M |
| 2022-03-31 | $5.00K | $353.90M | $-1.93M | $-91.62M | $260.36M | 3 month · $1.98M |
| 2021-12-31 | $5.00K | $351.85M | $-514.00K | $-76.96M | $274.38M | 12 month · $4.40M |
| 2021-09-30 | $5.00K | $349.68M | $-24.00K | $-64.26M | $285.40M | 3 month · $1.55M |
| 2021-06-30 | $5.00K | $348.10M | $-33.00K | $-51.31M | $296.75M | 3 month · $687.00K |
| 2021-03-31 | $5.00K | $347.40M | $-54.00K | $-40.96M | $306.39M | 3 month · $296.00K |
| 2020-12-31 | (m) | $727.00K | (m) | $-34.15M | $-33.42M | 12 month · $354.00K |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-27.27M | 3 month · $70.00K |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-23.76M | 3 month · $49.00K |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-19.98M | 3 month · $45.00K |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-16.85M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |